Benzinga | Dec 11, 2020 08:04AM EST

Evofem Biosciences Announces Orange Book Listing Of Two US Patents For Phexxi

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced that two U.S. patents which cover Phexxi(r) (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Phexxi is the first and only FDA-approved, non-hormonal contraceptive vaginal gel that is designed to be used immediately before or up to an hour before intercourse. It was approved in May 2020 and is now available in the U.S. by prescription. Phexxi works to maintain vaginal pH, which reduces sperm mobility, lowering the chance of sperm reaching the egg.